• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Scaling its Investment Platform in Minimally Invasive Care, Intuitive Ventures Appoints Terri Burke as Senior Partner and Ross Jaffe as Venture Advisor

    3/6/25 8:00:00 AM ET
    $EW
    Industrial Specialties
    Health Care
    Get the next $EW alert in real time by email

    Intuitive Ventures today announced the appointment of Terri Burke, former head medtech investments at Epidarex Capital and a seasoned operator, as Senior Partner and Dr. Ross Jaffe, a co-founder of Versant Ventures, as Venture Advisor. Both medtech veterans, they will help support the continued growth of Intuitive Ventures in investing in start-ups reimagining the future of minimally invasive care.

    With more than two decades of medtech investing and operational leadership experience, Burke will help support the growth of the firm's investment platform. With over $250 million in assets under management, Intuitive Ventures invests in founders tackling large, meaningful problems that positively impact patient outcomes and the delivery of care through advanced technology.

    "I am excited to have Terri join the team," said Murielle Thinard McLane, President and Managing Partner at Intuitive Ventures. "She brings extensive experience as a medtech institutional investor and hands-on operator at both public companies and early-stage start-ups."

    Most recently, Burke was a Venture Partner and Head of Medtech Investments at Epidarex Capital, where she led the firm's Fund III US/UK investment strategy, deal flow and medtech brand. Burke also previously co-founded and served as CEO at Protaryx Medical, a pioneering company that enhances access and procedural efficiency in structural heart and electrophysiology interventions. Previously, she served in various senior leadership roles at Edwards Lifesciences (NYSE:EW), including Vice President of Global Marketing and Business Development where she streamlined and re-focused the heart valve business to help drive growth.

    Burke is currently a board advisor for Raydiant Oximetry, a Trustee for the Roessler-Chadwick Foundation where she also serves as Chair of the Finance Committee and member of the Executive Committee, and a Director for the Roessler-Chadwick Foundation Group.

    "Throughout my career, I've had the opportunity to position and launch products, acquire technologies and companies, fund start-up companies and raise capital for my own company – working on every side and at every stage of the entrepreneurial journey," said Burke. "I'm eager to join the team as Intuitive Ventures continues to scale its impact across the global medtech and digital health markets. I also look forward to actively collaborating with the firm's portfolio companies to support groundbreaking innovations for significant unmet clinical needs."

    In addition to the appointment of Burke, Intuitive Ventures recently welcomed Dr. Ross Jaffe as a Venture Advisor. Dr. Jaffe brings extensive experience in medical devices, diagnostics/monitoring, drug delivery, healthcare software, and venture firm management to his role advising Intuitive Ventures.

    Dr. Jaffe was one of the founders of Versant Ventures, where he remains a Legacy Managing Director, and was previously a General Partner at Brentwood Venture Capital, where he started his career as one of the first physicians in the venture capital industry. After stepping back from active investing for Versant, Dr. Jaffe also served as a Venture Advisor for New Enterprise Associates. He is currently a co-founder and Board Chair of Faro Health, an innovative clinical trial software company.

    Since its launch in 2020, Intuitive Ventures has backed 13 transformative startups working to fulfill major unmet patient needs. In 2024, the firm announced its $150 million Fund II, which is being deployed across three core areas of investment: improving healthcare access and coordination; driving precision diagnostics and interventions; and leveraging healthcare data to enhance minimally invasive care.

    About Intuitive Ventures

    Intuitive Ventures invests in companies reimagining the future of minimally invasive care. Our global focus spans diagnostics, MedTech, therapies, and digital health. With $250 million in assets under management, we back teams that share our passion for advancing positive patient outcomes, improving provider experience, and increasing the efficiency of healthcare delivery. Intuitive Ventures' experience as operators and clinicians combined with unique access to Intuitive Surgical's technical and commercial reach enables our portfolio companies to revolutionize the delivery of patient care. More information and future updates can be found at: https://ventures.intuitive.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250306137039/en/

    Media Contact

    Julie Bishop

    julie@walkercomms.com

    Get the next $EW alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EW

    DatePrice TargetRatingAnalyst
    4/1/2026$92.00Peer Perform → Outperform
    Wolfe Research
    1/9/2026$97.00Hold → Buy
    TD Cowen
    12/18/2025$100.00Neutral → Overweight
    Analyst
    11/3/2025$96.00Mkt Perform → Outperform
    Raymond James
    10/29/2025Underperform → Peer Perform
    Wolfe Research
    10/29/2025$98.00Hold → Buy
    Jefferies
    10/8/2025Outperform → Perform
    Oppenheimer
    10/7/2025$88.00In-line → Outperform
    Evercore ISI
    More analyst ratings

    $EW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Edwards Lifesciences to Host Earnings Conference Call on July 23, 2026

    Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended June 30, 2026 after the market closes on Thursday July 23, and will host a conference call at 5:00 p.m. ET that day to discuss those results.To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com.About Edwards LifesciencesEdwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stake

    7/16/26 7:05:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards’ Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves

    Edwards Lifesciences (NYSE:EW) today announced new data presented at New York Valves 2026, the annual conference organized by the Cardiovascular Research Foundation, which reinforce the company's leadership in advancing high-quality scientific evidence and innovating for patients. These new data – spanning aortic, mitral and tricuspid therapies – provide further understanding of the complexity of structural heart disease and the need for innovative treatment options. Ahead of the planned full clinical presentation at TCT later this year, the baseline characteristics of the PROGRESS trial presented today provide new insights into the heterogeneous nature of moderate aortic stenosis (AS) pa

    6/26/26 10:15:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences Announces Appointment of CFO

    Edwards Lifesciences (NYSE:EW) today announced the appointment of Theodora ("Doretta") Mistras as the company's corporate vice president and chief financial officer (CFO), effective at the end of May. Mistras will succeed Scott Ullem, who announced in October his planned transition from the CFO role. Mistras joins Edwards from Viatris, where she has served as CFO since March 2024, leading the company's global finance organization and overseeing financial planning, reporting and operational finance across a complex, global business. Prior to Viatris, she was a managing director in healthcare investment banking at Citigroup Global Markets, and earlier in her career held senior leadership ro

    5/4/26 4:45:00 PM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    SEC Filings

    View All

    SEC Form 11-K filed by Edwards Lifesciences Corporation

    11-K - Edwards Lifesciences Corp (0001099800) (Filer)

    6/12/26 4:29:24 PM ET
    $EW
    Industrial Specialties
    Health Care

    SEC Form 11-K filed by Edwards Lifesciences Corporation

    11-K - Edwards Lifesciences Corp (0001099800) (Filer)

    6/12/26 4:27:32 PM ET
    $EW
    Industrial Specialties
    Health Care

    SEC Form SD filed by Edwards Lifesciences Corporation

    SD - Edwards Lifesciences Corp (0001099800) (Filer)

    5/27/26 4:20:57 PM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Zovighian Bernard J covered exercise/tax liability with 4,245 shares, converted options into 6,265 shares and bought $49,753 worth of shares (580 units at $85.74), increasing direct ownership by 5% to 46,836 units (SEC Form 4)

    4 - Edwards Lifesciences Corp (0001099800) (Issuer)

    5/7/24 5:53:27 PM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Edwards Lifesciences upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Edwards Lifesciences from Peer Perform to Outperform and set a new price target of $92.00

    4/1/26 8:10:23 AM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences upgraded by TD Cowen with a new price target

    TD Cowen upgraded Edwards Lifesciences from Hold to Buy and set a new price target of $97.00

    1/9/26 8:27:58 AM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences upgraded by Analyst with a new price target

    Analyst upgraded Edwards Lifesciences from Neutral to Overweight and set a new price target of $100.00

    12/18/25 8:41:18 AM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Leadership Updates

    Live Leadership Updates

    View All

    Edwards Lifesciences Announces Appointment of CFO

    Edwards Lifesciences (NYSE:EW) today announced the appointment of Theodora ("Doretta") Mistras as the company's corporate vice president and chief financial officer (CFO), effective at the end of May. Mistras will succeed Scott Ullem, who announced in October his planned transition from the CFO role. Mistras joins Edwards from Viatris, where she has served as CFO since March 2024, leading the company's global finance organization and overseeing financial planning, reporting and operational finance across a complex, global business. Prior to Viatris, she was a managing director in healthcare investment banking at Citigroup Global Markets, and earlier in her career held senior leadership ro

    5/4/26 4:45:00 PM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences Announces CFO Transition Plan

    Edwards Lifesciences (NYSE:EW) today announced that Scott Ullem, the company's chief financial officer, has decided to transition from his role by midyear 2026. While the company initiates a selection process to appoint a new CFO, this planned transition will enable continuity and a smooth transfer of responsibilities. Following the appointment of a new CFO, Ullem will continue in an advisory role. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are insp

    10/30/25 4:15:00 PM ET
    $EW
    Industrial Specialties
    Health Care

    Pulnovo Medical Names Dr. Francis Duhay as Global Chief Medical Officer

    SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Pulnovo Medical, a global leader in mechanism-driven therapies for Pulmonary Hypertension (PH) and Heart Failure (HF), today announced the appointment of Francis Duhay, MD, MBA, FACS as Global Chief Medical Officer. Dr. Duhay, a board-certified General and Cardiothoracic Surgeon, brings over 25 years of experience in clinical medicine, medical device innovation, and executive leadership. As former Chief Medical Officer at Edwards Lifesciences (NYSE:EW), he played a decisive role in the development, clinical validation, and worldwide adoption of Transcatheter Aortic Valve Replacement (TAVR)—a transformative therapy now recognized as one of the most suc

    8/25/25 4:33:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Financials

    Live finance-specific insights

    View All

    Edwards Lifesciences to Host Earnings Conference Call on July 23, 2026

    Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended June 30, 2026 after the market closes on Thursday July 23, and will host a conference call at 5:00 p.m. ET that day to discuss those results.To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com.About Edwards LifesciencesEdwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stake

    7/16/26 7:05:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences Reports First Quarter Results

    Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended March 31, 2026. Highlights and Outlook Q1 sales grew 16.7% to $1.65 billion1, constant currency2 sales grew 12.7% Q1 TAVR sales grew 14.4% to $1.20 billion1; constant currency2 sales grew 11.0% Q1 TMTT sales of $173 million1,3, driven by repair and replacement therapies Q1 EPS of $0.661; adjusted2 EPS of $0.781 Raising FY 2026 constant currency2 sales growth guidance to 9% to 11% from 8% to 10% Raising FY 2026 adjusted2 EPS guidance midpoint; new range of $2.95 to $3.05 from $2.90 to $3.05 Renewed clinical focus on proactive disease management with differentiated SAPIEN TAVR Compl

    4/23/26 4:15:00 PM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences to Host Earnings Conference Call on April 23, 2026

    Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended March 31, 2026 after the market closes on Thursday April 23, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and heal

    4/16/26 7:05:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CVP, EMEACLA Bruls Annette covered exercise/tax liability with 109 shares, decreasing direct ownership by 0.53% to 20,628 units (SEC Form 4) (for withholding tax)

    4 - Edwards Lifesciences Corp (0001099800) (Issuer)

    7/13/26 4:09:27 PM ET
    $EW
    Industrial Specialties
    Health Care

    CVP, Chief Financial Officer Mistras Theodora was granted 99,920 shares (SEC Form 4)

    4 - Edwards Lifesciences Corp (0001099800) (Issuer)

    7/10/26 5:11:14 PM ET
    $EW
    Industrial Specialties
    Health Care

    CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,762 worth of shares (619 units at $91.70) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Edwards Lifesciences Corp (0001099800) (Issuer)

    7/10/26 5:04:11 PM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Edwards Lifesciences Corporation

    SC 13G - Edwards Lifesciences Corp (0001099800) (Subject)

    11/8/24 10:34:33 AM ET
    $EW
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Edwards Lifesciences Corporation

    SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)

    10/4/24 2:14:28 PM ET
    $EW
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Edwards Lifesciences Corporation (Amendment)

    SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)

    2/13/24 5:04:42 PM ET
    $EW
    Industrial Specialties
    Health Care